Beth Purchase
Institute of Cancer Research
3 Papers
5 Citations
Beth Purchase is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Cancer & Palbociclib. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
Bristi Basu,Matthew G Krebs,Raghav Sundar,Raghav Sundar,Richard H. Wilson,James Spicer,Robert H. Jones,Michael Brada,Denis Talbot,N. Steele,A.H. Ingles Garces,Wolfram Brugger,Elizabeth A. Harrington,Joseph R. Evans,Emma Hall,Holly Tovey,F.M. de Oliveira,Susana Carreira,Karen E Swales,Ruth Ruddle,Florence I. Raynaud,Beth Purchase,J.C. Dawes,Mahesh K. B. Parmar,Alison Turner,Nina Tunariu,Susana Banerjee,J.S. de Bono,Udai Banerji +28 more
TL;DR: A highly active and well-tolerated combination of vistusertib, administered as an intermittent schedule with weekly paclitaxel, in patients with HGSOC and SqNSCLC is reported.
33
P3.02c-003 TAX-TORC: The novel combination of weekly paclitaxel and the dual mTORC1/2 inhibitor AZD2014 for the treatment of squamous NSCLC.
Matthew G Krebs,James Spicer,Nicola Steele,Denis Talbot,Michael Brada,Richard H. Wilson,R. Jones,Bristi Basu,J.C. Dawes,Mona Parmar,Beth Purchase,Alison Turner,Emma Hall,Holly Tovey,Udai Banerji,Timothy A. Yap +15 more
4
A phase I trial of selective PI3K inhibitor taselisib (tas) plus palbociclib (palb) with and without endocrine therapy incorporating pharmacodynamic (PD) studies in patients (pts) with advanced cancers.
Joline Si Jing Lim,U. Asghar,Nikolaos Diamantis,Sarah Emily Ward,Mona Parmar,Beth Purchase,Florence I. Raynaud,Karen E Swales,Sarah Hrebien,Emma Hall,Holly Tovey,Hannah Bye,Paula Proszek,Juanita Lopez,Alison Turner,Johann S. de Bono,Udai Banerji,Timothy A. Yap,Nicholas C. Turner +18 more
TL;DR: This investigator-initiated study investigated safety and tolerability, pharmacokinetics, PD and antitumor activity of Tas+Palb, with addition of ET in dose expansion, with result that Tas, Palb and ET is synergistic in preclinical models.
2